Abbisko raises $28M in series A

Abbisko Therapeutics (Shanghai, China) said it raised $28 million in a series A financing from Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital.

Abbisko's website lists three preclinical compounds, including lead candidate ABSK001 for oncology. The company intends to develop small molecule immunomodulators for cancers prevalent in Asia, as well as other diseases. Abbisko did not respond to inquiries...